Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Phase 1

Active, not recruiting

Conditions: Alzheimers Disease

Interventions: Drug: RO7126209
Drug: Placebo

First Posted Date: 2020-11-20

Last Posted Date: 2025-06-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 285

Registration Number: NCT04639050

Locations: 🇺🇸
JEM Research LLC, Atlantis, Florida, United States
🇺🇸
K2 Medical Research-Winter Garden, Clermont, Florida, United States
🇺🇸
K2 Medical Research - The Villages, Lady Lake, Florida, United States

and more 42 locations

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Phase 3

Active, not recruiting

Conditions: Primary Membranous Nephropathy

Interventions: Drug: Obinutuzumab
Drug: Tacrolimus
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2020-11-16

Last Posted Date: 2025-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 142

Registration Number: NCT04629248

Locations: 🇮🇹
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia, Italy
🇦🇷
Hospital Britanico Buenos Aires, Buenos Aires, Argentina
🇫🇷
Hopital Henri Mondor, Creteil, France

and more 47 locations

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Radiation: Thoracic radiation therapy (TRT)

First Posted Date: 2020-11-09

Last Posted Date: 2024-07-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 56

Registration Number: NCT04622228

Locations: 🇨🇳
Cancer Hospital , Chinese Academy of Medical, Beijing City, China
🇨🇳
West China Hospital - Sichuan University, Chengdu City, China
🇨🇳
Second Affiliated Hospital of Third Military Medical University, Chongqing, China

and more 5 locations

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pemetrexed
Drug: Tiragolumab Matching Placebo
Drug: Carboplatin
Drug: Cisplatin
Drug: Pembrolizumab

First Posted Date: 2020-11-06

Last Posted Date: 2025-06-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT04619797

Locations: 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸
Hospital Univ. Nuestra Señora de Valme, Sevilla, Spain
🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain

and more 119 locations

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 1

Completed

Conditions: Geographic Atrophy

Interventions: Drug: RO7303359

First Posted Date: 2020-11-04

Last Posted Date: 2023-03-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 37

Registration Number: NCT04615325

Locations: 🇺🇸
California Retina Consultants - Santa Maria, Santa Maria, California, United States
🇺🇸
University Retina and Macula Associates, PC, Oak Forest, Illinois, United States
🇺🇸
Austin Clinical Research LLC, Austin, Texas, United States

and more 9 locations

A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Carcinoma, Non-Small Cell Lung

Interventions: Drug: Placebo
Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Paclitaxel

First Posted Date: 2020-11-02

Last Posted Date: 2021-06-16

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT04611776

A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: RO7223280

First Posted Date: 2020-10-28

Last Posted Date: 2023-04-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 124

Registration Number: NCT04605718

Locations: 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Entrectinib
Drug: Crizotinib

First Posted Date: 2020-10-27

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 220

Registration Number: NCT04603807

Locations: 🇧🇷
Hospital Sao Rafael - HSR, Salvador, Bahia, Brazil
🇧🇷
Oncocentro Serviços Médicos e Hospitalares Ltda, Fortaleza, Ceará, Brazil
🇧🇷
Hospitais Integrados da Gavea S/A, Brasilia, Distrito Federal, Brazil

and more 88 locations

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Faricimab

First Posted Date: 2020-10-22

Last Posted Date: 2023-12-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 99

Registration Number: NCT04597918

Locations: 🇺🇸
Austin Research Center for Retina, Austin, Texas, United States
🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany
🇮🇹
Ospedale San Giuseppe; U.O. Oculistica, Milano, Lombardia, Italy

and more 20 locations

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Phase 3

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: PRM-151 (Zinpentraxin Alfa)

First Posted Date: 2020-10-20

Last Posted Date: 2024-05-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 117

Registration Number: NCT04594707

Locations: 🇺🇸
Sarasota County Public Hospital, Sarasota, Florida, United States
🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Pulmonix Research, Greensboro, North Carolina, United States

and more 245 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy